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 Biomaterials

Radical scavenging of poly(methyl
methacrylate) bone cement by rifampin
and clinically relevant properties of the
rifampin-loaded cement
Objectives
The objective of this study was to characterize the effect of rifampin incorporation into
poly(methyl methacrylate) (PMMA) bone cement. While incompatibilities between the
two materials have been previously noted, we sought to identify and quantify the cause
of rifampin’s effects, including alterations in curing properties, mechanical strength, and
residual monomer content.

Methods
Four cement groups were prepared using commercial PMMA bone cement: a control; one
with 1 g of rifampin; and one each with equimolar amounts of ascorbic acid or hydroquinone
relative to the amount of rifampin added. The handling properties, setting time, exothermic
output, and monomer loss were measured throughout curing. The mechanical strength of
each group was tested over 14 days. A radical scavenging assay was used to assess the scavenging abilities of rifampin and its individual moieties.

Results
Compared with control, the rifampin-incorporated cement had a prolonged setting time
and a reduction in exothermic output during polymerization. The rifampin cement showed
significantly reduced strength and was below the orthopaedic weight-bearing threshold of
70 MPa. Based on the radical scavenging assay and strength tests, the hydroquinone structure within rifampin was identified as the polymerization inhibitor.
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The incorporation of rifampin into PMMA bone cement interferes with the cement’s radical
polymerization. This interference is due to the hydroquinone moiety within rifampin. This
combination alters the cement’s handling and curing properties, and lowers the strength
below the threshold for weight-bearing applications. Additionally, the incomplete polymerization leads to increased toxic monomer output, which discourages its use even in nonweight-bearing applications.
Cite this article: Bone Joint Res 2019;8:81–89.
Keywords: Poly(methyl methacrylate) (PMMA), Rifampin, Strength, Radical

Article focus

 The purpose of this study was to characterize rifampin-loaded poly(methyl methacrylate) (PMMA) bone cement.
 The cause of chemical incompatibility
between rifampin and the cement was
investigated, and various clinically relevant properties of the rifampin-loaded
cement were determined.
 Surgical contraindications of rifampinloaded PMMA bone cement were
identified.

Key messages

 The addition of rifampin to PMMA bone
cement interferes with the radical polymerization mechanism, resulting in delayed
cement curing and reduced compressive
strength.
 The hydroquinone structure within
rifampin acts as a radical scavenger.
 The resulting incomplete polymerization
of the cement causes unreacted toxic
monomer to leach from the cement over
time.
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Strengths and limitations

 A multitude of tests were performed to give a full
characterization of rifampin-loaded PMMA bone
cement.
 Compressive properties of, and unreacted monomer
loss from, the cement may vary in vivo.

Introduction

Infection associated with orthopaedic surgery, and more
specifically total joint arthroplasty (TJA), is a severe complication to patients and burdens the healthcare system.1
While prosthetic joint infection (PJI) occurs in only 1% to
3% of TJA cases, the associated costs to the United States
healthcare system are projected to be US$1.62 billion by
the year 2020.2-4 Poly(methyl methacrylate) (PMMA) is
the major component of commercially available orthopaedic bone cement. It is used to anchor the implant in
the bone during primary cases, and in fabricating weightbearing spacers during revision surgery. Bone cement is
routinely loaded with antibiotic(s), both prophylactically
and as part of infected revision as a means of delivering
high local doses of antibiotics, while avoiding the systemic toxicity associated with intravenous administration.5,6 Staphylococcus aureus (S. aureus) and
coagulase-negative Staphylococcus spp. are the most
prevalent infectious organisms following orthopaedic
surgery.7 Therefore, glycopeptide antibiotics such as vancomycin, and aminoglycosides such as gentamicin, are
the most commonly incorporated drugs to treat PJI.8-10
Often, PJI will result in the formation of a biofilm on or
near the implant. A biofilm is a collection of bacteria that
forms a protective barrier with innate resistance to antibiotics, and has a high propensity to develop on inert surfaces such as implants and post-surgical bone.11,12 The
presence of these biofilms can make standard antibiotic
treatments ineffective, as both vancomycin and gentamicin are ineffective at clearing biofilms.13 Unlike vancomycin and gentamicin, rifampin is highly effective
against staphylococcal biofilms.13,14 Rifampin is used systemically in nearly all orthopaedic infection treatment
regimens, especially when the presence of methicillinresistant S. aureus (MRSA) is suspected.15 Even at easily
achievable infection site concentrations of 1 μg/ml to
8 μg/ml, rifampin can lead to a 5 log10 to 9 log10 reduction in bacterial biofilms and suppress bacterial recovery
by up to 24 hours post-treatment, which indicates almost
complete eradication of the biofilm.16
Recently, there has been increased interest in characterizing the ability of PMMA bone cement to act as a carrier for local delivery of rifampin to fight infection in the
presence of biofilms.16-18 In this regard, a number of
adverse effects associated with rifampin-loaded PMMA
bone cement have been reported.17,19 Rifampin, which
was approved in the United States in 1971, was recognized early on as having a detrimental effect on PMMA

polymerization and strength, and, as a result, has long
been discounted as a possible additive to bone cement.
Although clearly recognized, the cause of rifampin’s
incompatibility has never been experimentally determined, nor has the effect been quantified.
An understanding of possible mechanisms for the
effect of rifampin on PMMA bone cement may be
obtained by analyzing the chemical structure and properties of the antibiotic. Rifampin contains both a hydroquinone and piperazine moiety within its structure
(Fig. 1). Both are known radical scavengers. The ability of
rifampin to act as a radical scavenger was noted previously by Tomiyama et al20 in a 1996 study, where they
used rifampin to inhibit β protein aggregation in an
Alzheimer’s model. Pozdeeva and Denisov21 investigated
the mechanism of hydroquinone-mediated oxidation of
methyl methacrylate (MMA), and determined its impact
on slowing the rate of the reaction. Aware of the scavenging potential of rifampin, McPherson and Portugal19 proposed that rifampin reacted with the cement’s initiators
to quench the polymerization process. They reported
increases in cement curing time, but this work was a case
study and mechanical properties were not determined.
Little experimental work has been performed to understand and overcome rifampin’s effect on PMMA. One
paper by Rose et al18 evaluated rifampin release from
poly(styrene-co-MMA monomer) (PS-PMMA) films rather
than from PMMA bone cement itself. In two separate studies by Sanchez et al16 and Shiels et al,17 the elution and
effectiveness of rifampin-loaded PMMA bone cement
beads using in vitro bioassays16 and in a rat infection
model17 were investigated. While the investigators found
reasonable antibacterial effectiveness, they also remarked
on the slow and incomplete curing of the cement. Low
strength and stiffness of rifampin-loaded cement remain
major shortcomings for weight-bearing applications. In
the referenced studies, the mechanism of rifampin’s chemical interaction with the cement was not investigated.
The purpose of the present study was to elucidate the
interaction between rifampin and a commercially available PMMA bone cement, and to determine a number of
clinically relevant properties of the composite material.
These characteristics include its biomechanical strength
and modulus over time, surface morphology, curing
time, and the amount of unreacted monomer still present within the cement. Additionally, we sought to utilize
a radical scavenging assay to verify experimentally the
mechanism of interaction between rifampin and the
cement. We hypothesized that the hydroquinone unit
contained within rifampin acts as a radical scavenger,
and is responsible for the interaction of rifampin with the
cement’s polymerization process. Two known radical
scavenging molecules, ascorbic acid and hydroquinone,
were also added to PMMA bone cement to further illustrate and verify this chemical interaction.
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Fig. 1
The chemical structure of rifampin. The hydroquinone (1) and piperazine (2) moieties have been labelled.

Table I. Cement group composition and study role
Cement group

Additive

Amount, g (mol)

Purpose

CON
RIF
AA
HQ

None
Rifampin
Ascorbic acid
Hydroquinone

N/A
1.00 (1.2 × 10-3)
0.21 (1.2 × 10-3)
0.13 (1.2 × 10-3)

Negative control
Experimental
Positive control
Positive control

CON, negative control without any additive; N/A, not applicable; RIF, loaded with 1 g of rifampin; AA, positive control loaded with ascorbic acid; HQ, positive
control loaded with hydroquinone

Materials and Methods

Materials. The PMMA bone cement brand used was

SmartSet MV (DePuy Synthes, Blackpool, United
Kingdom). The cement was sterile and used before its
expiration date. Four groups of cement were prepared:
a negative control without any additive (CON); one
loaded with 1 g of rifampin (RIF); and two positive controls loaded with either ascorbic acid (AA) or hydroquinone (HQ). In the RIF, AA, and HQ groups, the mass of
the additive was selected so that the molar amount was
the same (Table I).
A low dosage of rifampin (1 g) was chosen to differentiate between a ‘filler’ and ‘chemical’ interaction.
Hydroquinone and ascorbic acid were chosen based
upon their known functions as radical scavengers.21,22
Furthermore, it is to be noted that in many commercially available PMMA bone cement brands (including
SmartSet MV), hydroquinone is a constituent of the liquid component and serves to stabilize the polymerization reaction.23
Determination of curing properties. First, the additives
were mixed with the 40 g dry cement component, after
which the liquid monomer was added, and the material
was blended in a polymeric bowl that was open to the
ambient laboratory atmosphere. After initial mixing of
the cement, dough time (td) was determined as the time
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at which the dough was probed without adherence, serving as the first checkpoint towards polymerization. An aliquot (10 g) from each group was removed and placed
within a polytetrafluoroethylene (PTFE) thermocouple
mould based on the ASTM International standard specification for acrylic bone cement, ASTM F451-16.24 The
internal temperature of each group was recorded every
five seconds throughout curing using K-type thermocouple wires, along with OM-PL series data logger software
(OMEGA Engineering, Inc., Stamford, Connecticut). The
setting time (tset) of each cement group was calculated by
exothermic output, numerically the corresponding time
at which the internal temperature was equal to half the
sum of the maximum temperature and ambient temperature: tset = (Tmax + Tambient)/2.
Determination of compressive properties. The remainder of the cement dough that was not used in the determination of curing properties was pressed into a PTFE
cylindrical mould and allowed to cure at 37°C for one
hour, producing specimens with a diameter and height
of 6 mm and 12 mm, respectively.24 The specimens
were then inspected visually for defects. A total of 30
specimens without defects were selected randomly and
placed into individual 15 ml vials. Of the 30 specimens,
20 were immersed in 2.5 ml of 1 × phosphate-buffered
saline (PBS) (Ricca Chemical Co., Arlington, Texas), with
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Table II. Pertinent handling and curing properties of each cement group
as defined by the ASTM International standard specification for acrylic bone
cement, ASTM F451-1624
Cement group

td, mins

tset, mins

Tmax, °C

CON
RIF
AA
HQ

3.50
4.50
3.50
4.75

7.25
33.00
7.50
34.75

92.5
42.5
90.1
27.6

td, dough time; tset, setting time; Tmax, maximum temperature; CON,
negative control without any additive; RIF, loaded with 1 g of rifampin; AA,
positive control loaded with ascorbic acid; HQ, positive control loaded with
hydroquinone

the solution refreshed every 24 hours. The remaining ten
were kept dry.
All compression testing was carried out in accordance
with ASTM F451-16 to measure both compressive
strength and modulus.24 Testing was performed using an
MTS 858 Mini Bionix II hydraulic load frame (MTS Systems
Corp., Eden Prairie, Minnesota). The dry specimens from
each group were crushed 24 hours after curing, representing ‘Day 1’, while ten specimens from each group
were tested after seven and 14 days of soaking.
Radical scavenging assay. α,α-Diphenyl-β-picrylhydrazyl
(DPPH) is a molecule with a stabilized free radical, and
is often used for testing the antioxidant (radical scavenging) potential of plant extracts and pharmaceuticals.
Employed in an assay, it can be robust, highly reproducible, and usable with a wide range of antioxidant compounds.25 The procedure we used was adapted from the
study by Blois.26 Six analytes were used for this test: ascorbic acid; hydroquinone; rifampin; vancomycin (VANC);
gentamicin (GENT); and 1-methylpiperazine (PIP).
Gentamicin and vancomycin were chosen for comparison because they are antibiotics commonly and successfully incorporated into PMMA bone cement. Each analyte
was incubated with DPPH in spectroscopy-grade methanol (Thermo Fisher Scientific, Fair Lawn, New Jersey) for
30 minutes in the dark, and the absorption at 515 nm
was measured. A loss of absorption at this wavelength
indicated radical quenching of the DPPH by the analyte. The absorption of each was compared with a DPPH
control solution of the same stock. The efficient concentration value required to quench or reduce the control
absorbance by 50%, EC50, was used to quantify the effect
of the analyte as proposed by Bondet et al.27 Thus, the
lower the EC50, the higher the radical scavenging potency
of the analyte. Each analyte was tested in triplicate.
Cement surface morphology. A qualitative surface analysis of both CON and RIF cement pellets was performed
via scanning electron microscopy (SEM). The CON and
RIF specimens were chosen to determine the influence
of rifampin incorporation on the surface morphology
of the cement. A single dry specimen from each group
was sputter-coated with an 80:20 gold-palladium alloy.
Images were taken with 100 × magnification using a
scanning electron microscope (Hitachi S-2700; Hitachi,

Tokyo, Japan) equipped with a Quartz PCI digital capture
(Quartz Imaging Corporation, Vancouver, Canada).
Volatile monomer weight loss quantification. In order to
quantify the amount of volatile monomer leaching from
the cement, fresh batches of both CON and RIF cement
were prepared. Each of these cements was mixed as
before until td was reached, at which point the cement
was spread throughout the bowl and placed on an
enclosed pre-tared scale. The mass of each was recorded
over the course of 24 hours.
Statistical analysis. For each of the quantitative properties
determined, the results are presented as ± 1 sd. Statistical
analysis was performed using one-way analysis of variance
(ANOVA) and post hoc unpaired Student’s t-tests (Microsoft
Excel; Microsoft, Redmond, Washington). Statistical differences were considered significant if p < 0.05.

Results

Curing properties. The td, tset, and Tmax of the cement

achieved during curing for each cement group are listed in
Table II. It is seen that td and tset of RIF are each significantly
higher than the corresponding value for CON. Visually, a
colour change from bright red to deep red-brown in RIF
was observed during cement mixing. For RIF and HQ, a
strong acrylic monomer scent was present and persistent
throughout mixing and curing. Greater polymerization
inhibition was observed in HQ. The AA showed no appreciable changes in td or tset, indicating that ascorbic acid
has no effect on the polymerization of the cement. The
exothermic output log for each cement group is displayed
in Figure 2. The CON and AA exhibited similar exothermic outputs, both achieving Tmax > 90°C within minutes,
while tailing off quickly. The RIF had a slow rise in exothermic temperature (Tmax = 42.5°C) over the course of 45
minutes, with slow dissipation thereafter. The HQ showed
a minimal increase in temperature throughout curing.
Compressive properties. The compressive strengths of
the cements are presented in Figure 3. Each group varied significantly from CON during each timepoint (p <
0.05). The AA showed strength above 70 MPa (the minimum required strength, per ASTM F451) throughout the
testing period, and increased in strength significantly
over the course of seven days. The RIF had significantly
reduced strength when compared with CON and stayed
well below 70 MPa over the course of 14 days. The HQ
exhibited minimal strength and remained elastic, even
after 14 days.
The modulus for each composite group is shown in
Figure 4. The moduli of CON and AA were not significantly different from one another over the course of 14
days. The modulus of RIF was significantly lower than
that of CON over the course of 14 days. The HQ showed
very low moduli over the course of 14 days.
Radical scavenging testing. The radical scavenging
results for each analyte are presented in Figure 5. Both
positive controls (AA and HQ) behaved as potent radical
BONE & JOINT RESEARCH
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Fig. 2
Line graph showing a sample curing temperature versus curing time profiles. CON, negative control without any additive; RIF, loaded with 1 g of rifampin; AA,
positive control loaded with ascorbic acid; HQ, positive control loaded with hydroquinone.
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Fig. 3
Chart summarizing the compressive strength values. An asterisk (*) denotes a significant difference from control, p < 0.05. The dashed line indicates the 70 MPa
threshold. Ten specimens were tested from each group. CON, negative control without any additive; RIF, loaded with 1 g of rifampin; AA, positive control loaded
with ascorbic acid; HQ, positive control loaded with hydroquinone.

scavengers at low concentrations (EC50). Likewise, RIF
exhibited potent scavenging, although not quite as
much as AA and HQ. The VANC and GENT were unreactive towards the DPPH radical. 1-methylpiperazine, while
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known to function as a radical scavenger, did not show
an appreciable effect at comparable concentrations.
Surface morphologies. The results for CON and RIF are displayed in Figure 6. Qualitatively, the surface topography
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Fig. 4
Chart summarizing the compressive modulus values. An asterisk (*) denotes a significant difference from control, p < 0.05. Ten specimens were tested from
each group. CON, negative control without any additive; RIF, loaded with 1 g of rifampin; AA, positive control loaded with ascorbic acid; HQ, positive control
loaded with hydroquinone.
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Fig. 5
Chart summarizing the computed EC50 results. An asterisk (*) denotes a significant difference from rifampin (RIF). Three specimens were tested from each group.
AA, ascorbic acid; HQ, hydroquinone; VANC, vancomycin; GENT, gentamicin; PIP, 1-methylpiperazine.

of CON appears to be solid without major pores and is
generally homogeneous. Conversely, the surface of RIF is
inconsistent and contains major structural defects in the
form of deep pores and rifts.
Volatile monomer weight loss. The CON and RIF cements
lost 0.40 g and 2.42 g over 24 hours, respectively, representing a 500% increased loss in volatile monomer
from RIF. The CON showed no appreciable weight loss
after 20 minutes. The RIF weight loss continued over the

course of 24 hours, revealing a steady release of monomer (Supplementary Fig. a).

Discussion

The effect of rifampin on the polymerization of PMMA
bone cement has been the subject of previous studies.17,19
However, in these studies, only limited attention was
given to both elucidating the mechanism involved in the
interaction between the materials and determining

BONE & JOINT RESEARCH
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Fig. 6a

Fig. 6b
a) Morphology of the surface of CON (negative control without any additive).
Magnified ×100. 115 mm × 89 mm (96 × 96 DPI). b) Morphology of the surface of RIF (loaded with 1 g of rifampin) specimen. Magnified ×100. 114 mm
× 89 mm (96 × 96 DPI).

clinically relevant properties of the rifampin-loaded
cement. These aspects are covered in the present work.
Regarding the cement curing, td and tset of RIF were each
significantly higher than the corresponding value for
CON. Over the course of 14 days, the compressive
strength of RIF was significantly lower than that of CON.
The reduction both in compressive strength and modulus from the addition of 1 g of rifampin to the cement is
not merely an artefact of the space occupied by the antibiotic, as this reduction is not seen with similar loading of
other antibiotics.28,29 Hydroquinone and rifampin gave
similarly low EC50 values, representing potent radical
scavenging activity. Thus, the hydroquinone moiety
within rifampin acts as a radical scavenger during PMMA
polymerization. It is directly responsible for the prolonged curing time, reduced mechanical strength, and
observed surface porosity of RIF stemming from incomplete cement polymerization. Furthermore, the effect of
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partial cement polymerization on toxic MMA release
from RIF has not been quantified previously in the literature. Our results show that, over the course of 24 hours,
a substantial amount of MMA was released from the RIF
specimen.
The addition of ascorbic acid had no appreciable
adverse effect on the handling and curing properties of
the cement with respect to control. Interestingly, the
DPPH assay revealed a similar EC50 value for ascorbic acid
compared with both hydroquinone and rifampin, highlighting its known nature as a potent radical scavenger.
While AA and CON showed similar curing properties, the
compressive strength of AA was significantly lower but
remained above 70 MPa. Investigation into this discrepancy revealed solubility issues within the curing cement.
Specifically, the high water solubility of the ascorbic acid
could have limited its ability to quench the radical chain
in the hydrophobic PMMA matrix.
The present study highlights the detrimental effects of
incorporating rifampin into PMMA bone cement.
Although the systemically administered combination
therapy of rifampin and another antibiotic is common,
rifampin is seldom used alone.14 Rifampin monotherapy
has been linked to a high likelihood of the emergence of
resistant pathogens, two of which are the most common
orthopaedic infection-causative organisms: S. aureus and
S. epidermis.30-32 While the incorporation of a second antibiotic, in addition to rifampin, into PMMA bone cement
may alleviate some of the concerns of pathogen resistance, the presence of rifampin may still cause the adverse
effects on the cement presented in this study.
Other studies have investigated ways to overcome the
deleterious effects of rifampin incorporation in commercial PMMA bone cement. One approach is the encapsulation of rifampin before it is mixed with the cement.
Sanz-Ruiz et al33 encapsulated rifampin and reported
effective elution of the antibiotic while preserving the
mechanical properties of PMMA. Similar results were
reported with the use of rifampin-filled cyclodextrin (CD)
microparticles. Cyphert et al34 found that the inclusion of
CD microparticles in PMMA resulted in similar mechanical properties to the PMMA control and may serve as a
refillable antibiotic delivery vehicle. While encapsulation
of rifampin is a potential technique that may be used to
include this drug in a commercial product, it is not currently an option for the orthopaedic surgeon in the operating theatre unless encapsulated rifampin is made
available as a separate product. Additional investigations
have included using alternative delivery vehicles, such as
bioresorbable carriers like sponges and calcium sulphate,
which utilize compositions other than PMMA and alleviate the concern of polymerization inhibition.35,36 While
these bioresorbable materials have the potential to
release therapeutic levels of rifampin, they have often
been limited to non-weight-bearing applications.
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In conclusion, the results of the present study demonstrate that the hydroquinone moiety within rifampin interferes with the polymerization of PMMA bone cement,
resulting in significantly prolonged cement curing and
setting times. This substantial delay represents a severe
disadvantage to surgeons by increasing operating time
and reducing the cement’s handleability.37 As a result, it
impacts the healthcare economy negatively and results in
a longer operating time, which is correlated with a higher
risk of infection when involving invasive procedures such
as joint arthroplasties.38-41 Additionally, compared with the
cement without rifampin, the compressive strength and
modulus of the rifampin-loaded cement are significantly
lower, and the amount of unreacted monomer loss is substantially higher. The lattermost characteristic potentially
poses a threat to the health of the patient and of the operating room staff. Toxic occupational exposure to MMA is
scarce in orthopaedic literature but common in dental literature, where olfactory lesions and local tissue necrosis
are reported.42 These findings suggest that the use of
rifampin-incorporated PMMA bone cement in its current
form should be discouraged for both weight-bearing and
non-weight-bearing applications in orthopaedics.

Supplementary Material

Line graph quantifying the amount of volatile monomer leaching from CON (negative control without
any additive) and RIF (loaded with 1 g of rifampin)
cements over the course of 24 hours.
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